"Small Molecule Inhibitors Of Kras G12c Mutant" in Patent Application Approval Process (USPTO 20240246968).

A patent application has been filed for small molecule inhibitors of the KRAS G12C mutant, which is commonly found in various types of cancer. The inhibitors target the active form of the mutant protein and have the potential to be used as a treatment for cancer. The patent application describes the compounds, their pharmaceutical compositions, and methods of using them to inhibit the activity of the KRAS G12C protein and treat cancer. The inventors highlight the need for novel compounds that can bind to the mutant protein and provide therapeutic opportunities for a wider population of patients. [Extracted from the article]

Copyright of Pharma Business Week is the property of NewsRx and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)